Vesteghem Charles, Brøndum Rasmus Froberg, Falkmer Ursula G, Pottegård Anton, Poulsen Laurids Østergaard, Bøgsted Martin
Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
Department of Hematology, Aalborg University Hospital, Aalborg, Denmark.
Clin Epidemiol. 2021 Nov 24;13:1085-1094. doi: 10.2147/CLEP.S332776. eCollection 2021.
The Danish National Patient Registry is a major resource for Danish epidemiology. Only a few studies have been conducted to check the validity of the reporting of systemic anticancer treatments. In this study, we assessed this validity for a range of cancer types over a long period of time.
We extracted systemic anticancer treatment procedures from the Danish National Patient Registry for patients with solid malignant tumors treated at the Department of Oncology at Aalborg University Hospital between 2009 and 2019 (12,014 patients with 215,293 drug records). These data were compared to records obtained from the antineoplastic prescription database used at the department. We estimated the sensitivity, positive predictive value (PPV), and F1-score defined as the harmonic mean of the sensitivity and the PPV.
There was an overall high concordance between the two datasets with a sensitivity and a PPV >92%. Treatments for brain, ovarian and endometrial cancers displayed lower concordance (81-89%). The validity was stable over the study period, with a slight drop during 2016-2017. Most drugs had a high validity with F1-scores above 90%. Fluorouracil, gemcitabine, pemetrexed, pembrolizumab, and nivolumab had F1-scores above 97%. Drugs that were introduced in the study period, such as lapatinib, palbociclib, erlotinib, pertuzumab, and panitumumab, yielded lower F1-scores due to the absence of specific registry codes early after introduction.
The Danish National Patient Registry can be used to reliably obtain information about systemic anticancer treatments, keeping in mind limitations for recently introduced drugs and for some types of cancer.
丹麦国家患者登记处是丹麦流行病学的重要资源。仅有少数研究对全身抗癌治疗报告的有效性进行了核查。在本研究中，我们在较长时间段内评估了一系列癌症类型的这种有效性。
我们从丹麦国家患者登记处提取了2009年至2019年在奥尔堡大学医院肿瘤科接受治疗的实体恶性肿瘤患者的全身抗癌治疗程序（12014例患者，有215293条药物记录）。将这些数据与该科室使用的抗肿瘤处方数据库中获取的记录进行比较。我们估算了敏感度、阳性预测值（PPV）以及定义为敏感度和PPV调和均值的F1分数。
两个数据集总体一致性较高，敏感度和PPV均>92%。脑癌、卵巢癌和子宫内膜癌的治疗显示出较低的一致性（81%-89%）。在研究期间，有效性保持稳定，在2016年至2017年期间略有下降。大多数药物有效性较高，F1分数高于90%。氟尿嘧啶、吉西他滨、培美曲塞、帕博利珠单抗和纳武利尤单抗的F1分数高于97%。在研究期间引入的药物，如拉帕替尼、哌柏西利、厄洛替尼、帕妥珠单抗和帕尼单抗，由于引入后早期缺乏特定的登记代码，F1分数较低。
丹麦国家患者登记处可用于可靠获取有关全身抗癌治疗的信息，但要注意近期引入药物和某些癌症类型存在的局限性。
